Verona Pharma plc

Verona Pharma plcverified

VRNA

Price:

$13

Market Cap:

$1.05B

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in...[Read more]

Industry

Biotechnology

IPO Date

2017-04-28

Stock Exchange

NASDAQ

Ticker

VRNA

The PE Ratio as of May 2024 (TTM) for Verona Pharma plc (VRNA) is -16.25

According to Verona Pharma plc’s latest financial reports and current stock price. The company's current PE Ratio is -16.25. This represents a change of -41.06% compared to the average of -27.57 of the last 4 quarters.

Verona Pharma plc (VRNA) Historical PE Ratio (quarterly & annually)

How has VRNA PE Ratio performed in the past?

The mean historical PE Ratio of Verona Pharma plc over the last ten years is -709.72. The current -16.25 PE Ratio has changed 128.96% with respect to the historical average. Over the past ten years (40 quarters), VRNA's PE Ratio was at its highest in in the June 2018 quarter at 427.10. The PE Ratio was at its lowest in in the December 2016 quarter at -262.92.

Quarterly (TTM)
Annual

Average

-709.72

Median

-32.52

Minimum

-3718.18

Maximum

-1.36

Verona Pharma plc (VRNA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Verona Pharma plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 253.23%

Maximum Annual PE Ratio = -1.36

Minimum Annual Increase = -99.03%

Minimum Annual PE Ratio = -3718.18

Quarterly (TTM)
Annual
YearPE RatioChange
2023-28.8714.78%
2022-25.15251.66%
2021-7.15102.54%
2020-3.53159.14%
2019-1.36-96.54%
2018-39.398.91%
2017-36.17-99.03%
2016-3718.18253.23%
2015-1052.61-51.82%
2014-2184.81161.58%

Verona Pharma plc (VRNA) Average PE Ratio

How has VRNA PE Ratio performed in the past?

The current PE Ratio of Verona Pharma plc (VRNA) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-20.39

5-year avg

-13.21

10-year avg

-709.72

Verona Pharma plc (VRNA) PE Ratio vs. Peers

How is VRNA’s PE Ratio compared to its peers?

Verona Pharma plc’s PE Ratio is less than Ventyx Biosciences, Inc. (-1.52), greater than IDEAYA Biosciences, Inc. (-23.60), less than Protagonist Therapeutics, Inc. (11.54), less than Syndax Pharmaceuticals, Inc. (-7.19), less than Day One Biopharmaceuticals, Inc. (-6.71), less than X4 Pharmaceuticals, Inc. (-1.44), less than Inozyme Pharma, Inc. (-3.68), less than Acumen Pharmaceuticals, Inc. (-3.90), greater than Mereo BioPharma Group plc (-63.73), less than Terns Pharmaceuticals, Inc. (-4.82), less than Amylyx Pharmaceuticals, Inc. (-1.75), greater than MoonLake Immunotherapeutics (-61.21), less than Mirati Therapeutics, Inc. (-5.32), less than Apellis Pharmaceuticals, Inc. (-12.17), less than Akero Therapeutics, Inc. (-6.59), less than Madrigal Pharmaceuticals, Inc. (-9.91), greater than Viking Therapeutics, Inc. (-73.96),

Build a custom stock screener for Verona Pharma plc (VRNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verona Pharma plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Verona Pharma plc (VRNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Verona Pharma plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Verona Pharma plc's PE Ratio?

How is the PE Ratio calculated for Verona Pharma plc (VRNA)?

What is the highest PE Ratio for Verona Pharma plc (VRNA)?

What is the 3-year average PE Ratio for Verona Pharma plc (VRNA)?

What is the 5-year average PE Ratio for Verona Pharma plc (VRNA)?

How does the current PE Ratio for Verona Pharma plc (VRNA) compare to its historical average?